Which of the following antipsychotics is not associated with QT issues?

Which of the following antipsychotics is not associated with QT issues?

• A. Latuda
• B. Rexulti
• C. Vraylar
• D. All of the above

Answer: (D)

The correct choice indicates that all listed antipsychotics are not associated with QT interval prolongation issues. Specifically: Latuda (lurasidone) has been noted to have a relatively low risk for QT prolongation. Clinical studies often evaluate the cardiac effects of medications, and Latuda has shown to have minimal impact on the QT interval compared to other antipsychotics. Rexulti (brexpiprazole) is also associated with a low incidence of QT prolongation. The safety profile of Rexulti highlights that it does not significantly affect cardiac conduction, making it safer in this regard. Vraylar (cariprazine) too has not been widely reported to cause QT prolongation. Its effects on the heart do not present a marked risk concerning the QT interval. Therefore, the assertion that all these antipsychotics do not have significant associations with QT issues is accurate. This is an important consideration for healthcare providers who must monitor the cardiovascular risk when prescribing antipsychotic medications, particularly in patients with existing heart conditions or those on other medications that may prolong the QT interval.

The correct choice indicates that all listed antipsychotics are not associated with QT interval prolongation issues. Specifically:

Latuda (lurasidone) has been noted to have a relatively low risk for QT prolongation. Clinical studies often evaluate the cardiac effects of medications, and Latuda has shown to have minimal impact on the QT interval compared to other antipsychotics.

Rexulti (brexpiprazole) is also associated with a low incidence of QT prolongation. The safety profile of Rexulti highlights that it does not significantly affect cardiac conduction, making it safer in this regard.

Vraylar (cariprazine) too has not been widely reported to cause QT prolongation. Its effects on the heart do not present a marked risk concerning the QT interval.

Therefore, the assertion that all these antipsychotics do not have significant associations with QT issues is accurate. This is an important consideration for healthcare providers who must monitor the cardiovascular risk when prescribing antipsychotic medications, particularly in patients with existing heart conditions or those on other medications that may prolong the QT interval.